Recent trials suggest that the use of PARP inhibitors (e.g., veliparib and olaparib) alone or in combination with chemotherapy or VEGF inhibitors significantly improves progression-free survival in first-line, as maintenance therapy and after first-line platinum exposure in ovarian cancer [25–27]. Here, VEGFA is linked to ovarian carcinoma.